An Open-label Long-term Safety Study of Buntanetap in Participants With AD
brief summary
This study will examine the long-term safety of buntanetap in participants with AD who have participated in a prior study of buntanetap in AD.
detailed description
ANVS-26001 will be a 24-month open-label safety study. Qualified participants will receive buntanetap 30 mg daily after a screening period of up to 42 days. ADAS-Cog13, ADCS-iADL, CDR, MMSE, WAIS-Coding, NPI-12, QoL-AD, CGI-S, and C-SSRS will be assessed by clinicians who have successfully completed the requisite certifications/trainings for each assessment. Each participant shall be assessed by the same clinician throughout the study. An independent Data and Safety Monitoring Board (DSMB) will assess treatment safety.
official title
An Open-label Clinical Trial Investigating the Long-term Safety of Buntanetap in Treating Participants With Alzheimer's Disease